Rivipansel Sodium

N/A

Report date: 2024/06/25 20:00:08
NME

Base Information

Drug NameRivipansel Sodium
Drug Alias Name利维泮塞rivipansel利维潘塞PF-6460031PF-06460031-02 +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionLeukocyte adhesion molecule-1 inhibitorsP-selectin inhibitorsSelectin E inhibitors
TargetsLeukocyte adhesion molecule-1Selectin EP-selectin
Therapy Area/IndicationsLiver DysfunctionPainAnemia, Sickle Cell +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesCrescent Biopharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBiossil IncCrescent Biopharma IncPfizer Inc
Active IndicationsN/A
Inactive IndicationsLiver DysfunctionPainAnemia, Sickle Cell +[4] 

Other Information

ATC CodeN/A
Related LinksKEGG